BRCAvantage®, Ashkenazi Jewish Screen with Reflex BRCAvantage®, Comprehensive
Use
This test is used to identify individuals with increased risk for hereditary breast and ovarian cancer syndrome, especially appropriate for individuals of Ashkenazi Jewish ancestry and/or with a personal or family history of cancers such as breast, ovarian, pancreatic, or high-grade prostate cancer. Reflex comprehensive testing is triggered if initial targeted screening is negative. Informed consent following genetic counseling is strongly recommended. ([questdiagnostics.com](https://www.questdiagnostics.com/healthcare-professionals/clinical-education-center/faq/faq322?utm_source=openai))
Special Instructions
Not provided.
Limitations
This test cannot detect all causes of hereditary predisposition to breast cancer. It is limited to BRCA1 and BRCA2 genes analyzed via the two-stage reflex workflow and does not test other genes associated with hereditary breast cancer. Rare or novel variants may remain unclear; false positives or negatives are possible. Results should be interpreted in clinical context and confirmed as needed. ([questdiagnostics.com](https://www.questdiagnostics.com/healthcare-professionals/clinical-education-center/faq/faq322?utm_source=openai))
Methodology
NGS
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Not provided.